The FDA has issued a warning to Merck & Co. for its 80mg dosage of Zocor. The warning was issued because of Zocor’s association with an increased risk of muscle injury. Zocor, also known as simvastin, is a cholesterol lowering drug. While statins in general tend be associated with a higher incidence of muscle injury, Zocor may leave patients susceptible to an even higher risk of muscle injury including rhabdomyolysis. Rhabdomyolysis is a critical form of muscle injury, which has the potential to cause serious kidney damage, kidney failure, and even fatality.